lapatinib has been researched along with bibw 2992 in 42 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (bibw 2992) | Trials (bibw 2992) | Recent Studies (post-2010) (bibw 2992) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 1,044 | 147 | 1,007 |
| Protein | Taxonomy | lapatinib (IC50) | bibw 2992 (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0361 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0168 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.037 | |
| Cytochrome P450 2E1 | Homo sapiens (human) | 0.014 | |
| Cytochrome P450 2C8 | Homo sapiens (human) | 0.037 | |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | 0.0007 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.037 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.0016 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.0024 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.38) | 29.6817 |
| 2010's | 33 (78.57) | 24.3611 |
| 2020's | 8 (19.05) | 2.80 |
| Authors | Studies |
|---|---|
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Guo, Y; He, J; Li, Y; Liu, M; Liu, Y; Xiao, J; Yu, W; Zhang, Q | 1 |
| Das, D; Hong, J | 1 |
| Asquith, CRM; Drewry, DH; East, MP; Havener, TM; Johnson, GL; Laitinen, T; Morris, DC; Naegeli, KM; Wells, CI; Zuercher, WJ | 1 |
| Basetti, V; Keesara, M; Maiti, P; Mansour, TS; Moghudula, AG; Pallepati, RR; Potluri, V | 1 |
| Abd El-Karim, SS; Ahmed, NS; Anwar, MM; El-Hallouty, SM; Srour, AM | 1 |
| Bauer, S; Baumann, M; Becker, C; Grabe, T; Hardick, J; Hodson, L; Jeyakumar, K; Ketzer, J; Keul, M; Kirschner, T; Klövekorn, P; Lategahn, J; Müller, MP; Niggenaber, J; Rauh, D; Terheyden, S; Tumbrink, HL; Unger, A; van Otterlo, WAL; Weisner, J | 1 |
| Chen, XB; Wang, S; Wang, SQ; Yu, B; Yuan, XH; Zhao, W | 1 |
| Amir, E; Ocaña, A | 1 |
| Awada, A; Bozovic-Spasojevic, I; Chow, L | 1 |
| Bozovic-Spasojevic, I; de Azambuja, E; Zardavas, D | 1 |
| Majem, M; Pallarès, C | 1 |
| Chekaluk, Y; Du, J; Gray, NS; Guo, Y; Kwiatkowski, DJ; Wu, CL; Zhang, J | 1 |
| Barlesi, F; Beau-Faller, M; Besse, B; Blons, H; Chouaid, C; Cortot, AB; Dansin, E; Diebold, J; Felip, E; Gautschi, O; Lepage, B; Mansuet-Lupo, A; Mazières, J; Milia, JD; Moro-Sibilot, D; Peters, S; Rouquette, I; Urban, T; Wislez, M | 1 |
| Aherne, ST; Clynes, M; Crown, J; Doolan, P; Madden, SF; O'Connor, R; O'Neill, F | 1 |
| Kümler, I; Nielsen, DL; Tuxen, MK | 1 |
| Gyõrffy, B; Mihály, Z | 1 |
| Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O | 1 |
| Kurzrock, R; Parker, BA; Schwab, R; Yan, M | 1 |
| Aleixo, SB; Arantes, H; Caleffi, M; Figueira, AC; Gutierrez, C; Nunes de Matos Neto, J; Osborne, CK; Reiriz, AB; Rimawi, MF; Rozas, AA; Solca, F; Souza, SC; Uttenreuther-Fischer, MM | 1 |
| Datta, J; Lang, JC; Mapp, AK; Pan, Q; Piao, L; Teknos, TN; Xie, X; Zhang, M | 1 |
| Di Luca, A; Henry, M; Meleady, P; O'Connor, R | 1 |
| Bertotti, A; Catalano, I; Leto, SM; Migliardi, G; Sassi, F; Throsby, M; Torri, V; Trusolino, L; Zanella, ER | 1 |
| Cosmai, L; Gallieni, M; Porta, C | 1 |
| Bachelot, T; Barriere, J; Bono, P; Ciruelos, E; Cortés, J; Dieras, V; Espié, M; Hurvitz, S; Joensuu, H; Kellokumpu-Lehtinen, PL; Kim, SB; Le Rhun, E; Nabholtz, JM; Ould-Kaci, M; Piacentini, F; Ro, J; Roux, F; Schneeweiss, A; Sohn, JH; Taguchi, J | 1 |
| Barlesi, F; Beau-Faller, M; Besse, B; Cappuzzo, F; Cortot, A; Dansin, E; Filleron, T; Fournel, P; Früh, M; Gautschi, O; Mazières, J; Milia, J; Monnet, I; Moro-Sibilot, D; Peters, S; Pless, M; Rosell, R; Westeel, V; Wislez, M | 1 |
| Grunt, TW; Gschwantler-Kaulich, D; Kölbl, H; Muhr, D; Singer, CF; Wagner, R | 1 |
| Mehra, R; Zibelman, M | 1 |
| Breslin, S; Lowry, MC; O'Driscoll, L | 1 |
| Bai, Y; Black, J; Carvajal-Hausdorf, DE; Rimm, DL; Santin, AD; Schalper, KA | 1 |
| Collins, DM; Crown, J; Davies, A; Edwards, C; Gately, K; Hughes, C; Madden, SF; O'Byrne, KJ; O'Donovan, N | 1 |
| Albiol-Chiva, J; Esteve-Romero, J; Peris-Vicente, J | 1 |
| Duchnowska, R; Jassem, J; Loibl, S | 1 |
| Browne, BC; Canonici, A; Collins, DM; Conlon, NT; Crown, J; Gaynor, N; Gullo, G; Ivers, L; O'Brien, NA; O'Donovan, N; Pedersen, K | 1 |
| Beißbarth, T; Bohnenberger, H; Conradi, LC; Gaedcke, J; Ghadimi, MB; Grade, M; Kisly, M; König, A; Liersch, T; Metzger, AL; Middel, P; Rüschoff, J; Spitzner, M | 1 |
| Fujita, M; Nakanishi, H; Nakata, S | 1 |
| Cheng, H; Huang, LC; Kannan, N; Li, S; Ma, P; Rasheed, K; Venkat, A; Wang, Y; Yeung, W | 1 |
| Agostinetto, E; Awada, A; Bruzzone, M; Ceppi, M; Danielli, L; de Azambuja, E; Kotecki, N; Lambertini, M; Martins-Branco, D; Nader-Marta, G | 1 |
| Feng, M; Li, Q; Liao, W; Qian, Z; Wen, F; Wu, Q; Yang, Y | 1 |
| Aiebchun, T; Choowongkomon, K; Kiriwan, D; Rasri, N; Siripattanapipong, S | 1 |
| Harada, Y; Ikeda, S; Kai, K; Kimura, S; Kitamura, S; Kurihara, Y; Nakamura, H; Nakamura, T; Sato, A; Sueoka, E; Sueoka-Aragane, N | 1 |
13 review(s) available for lapatinib and bibw 2992
| Article | Year |
|---|---|
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines | 2019 |
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2019 |
FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Molecular Structure; Neoplasms; Pyrimidines; United States; United States Food and Drug Administration | 2021 |
Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.
Topics: Afatinib; Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Forecasting; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Morpholines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Trastuzumab; Up-Regulation | 2009 |
New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms, Hormone-Dependent; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2012 |
An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents.
Topics: Afatinib; Aminoquinolines; Angiogenesis Inhibitors; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lapatinib; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Quinolines | 2013 |
A systematic review of dual targeting in HER2-positive breast cancer.
Topics: Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Neoadjuvant Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome; Up-Regulation | 2014 |
[HER2-positive breast cancer: available targeted agents and biomarkers for therapy response].
Topics: Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Everolimus; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Quinolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab | 2013 |
Renal toxicity of anticancer agents targeting HER2 and EGFR.
Topics: Acute Kidney Injury; Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Maytansine; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Renal Dialysis; Renal Insufficiency, Chronic; Trastuzumab | 2015 |
Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azepines; Carcinoma, Squamous Cell; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lapatinib; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Quinazolinones; Signal Transduction; Sirolimus | 2016 |
Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer.
Topics: Afatinib; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Receptor, ErbB-2 | 2018 |
Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis.
Topics: Afatinib; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors | 2022 |
2 trial(s) available for lapatinib and bibw 2992
| Article | Year |
|---|---|
A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 tr
Topics: Adult; Afatinib; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Canada; Disease Progression; Disease-Free Survival; Europe; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Republic of Korea; Risk Factors; Time Factors; Trastuzumab; Treatment Outcome; United States; Vinblastine; Vinorelbine | 2015 |
27 other study(ies) available for lapatinib and bibw 2992
| Article | Year |
|---|---|
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
Topics: Aminoquinolines; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chordoma; Drug Design; ErbB Receptors; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines | 2019 |
Lead generation of 1,2-dithiolanes as exon 19 and exon 21 mutant EGFR tyrosine kinase inhibitors.
Topics: Exons; Humans; Mutation; Protein Kinase Inhibitors; Thioctic Acid | 2019 |
Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; MCF-7 Cells; Molecular Docking Simulation; Protein Kinase Inhibitors; Quantitative Structure-Activity Relationship; Thiazoles | 2020 |
Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach.
Topics: Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Humans; Kinetics; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, ErbB-2; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
Topics: Afatinib; Antibiotics, Antineoplastic; Cell Line, Tumor; ErbB Receptors; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lapatinib; Loss of Heterozygosity; Naphthyridines; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Quinazolines; Resorcinols; Signal Transduction; Sirolimus; Tuberous Sclerosis Complex 1 Protein; Tuberous Sclerosis Complex 2 Protein; Tumor Cells, Cultured; Tumor Suppressor Proteins; Urinary Bladder Neoplasms | 2013 |
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; France; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutagenesis, Insertional; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Spain; Switzerland; Trastuzumab; Treatment Outcome | 2013 |
A gene expression profile indicative of early stage HER2 targeted therapy response.
Topics: Afatinib; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, ErbB-2; Time Factors | 2013 |
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines | 2013 |
HER2 aberrations in cancer: implications for therapy.
Topics: Ado-Trastuzumab Emtansine; Adult; Afatinib; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Male; Maytansine; Molecular Targeted Therapy; Mutation; Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Up-Regulation; Uterine Cervical Neoplasms | 2014 |
miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma.
Topics: Afatinib; Animals; Antineoplastic Agents; Base Sequence; Carcinogenesis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA-Binding Proteins; ErbB Receptors; Gene Expression; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Lapatinib; Mice, Nude; MicroRNAs; Neoplasm Transplantation; Proto-Oncogene Proteins c-ets; Quinazolines; RNA Interference; Signal Transduction; Transcription Factors; Tumor Burden | 2015 |
Label-free LC-MS analysis of HER2+ breast cancer cell line response to HER2 inhibitor treatment.
Topics: Afatinib; Breast Neoplasms; Cell Line, Tumor; Chromatography, Liquid; Female; Humans; Lapatinib; Mass Spectrometry; Protein Kinase Inhibitors; Proteomics; Quinazolines; Quinolines; Receptor, ErbB-2 | 2015 |
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Gastrointestinal Neoplasms; Gene Amplification; Gene Expression; Gene Knockdown Techniques; Humans; Lapatinib; Mice; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease-Free Survival; ErbB Receptors; Europe; Female; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2016 |
HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK.
Topics: Afatinib; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Inhibitory Concentration 50; JNK Mitogen-Activated Protein Kinases; Lapatinib; MAP Kinase Signaling System; Morpholines; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Quinazolines; STAT5 Transcription Factor | 2016 |
Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4.
Topics: Afatinib; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cytochrome P-450 CYP3A; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab; Up-Regulation | 2017 |
Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.
Topics: Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cohort Studies; Extracellular Space; Female; Fluorescent Antibody Technique; Humans; Intracellular Space; Lapatinib; Maytansine; Middle Aged; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Protein Domains; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Tissue Array Analysis; Trastuzumab; Uterine Neoplasms | 2017 |
Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
Topics: Afatinib; Antineoplastic Agents; Cell Line, Tumor; Cytotoxicity, Immunologic; Drug Interactions; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; L-Lactate Dehydrogenase; Lapatinib; MCF-7 Cells; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2017 |
Development of a method to determine axitinib, lapatinib and afatinib in plasma by micellar liquid chromatography and validation by the European Medicines Agency guidelines.
Topics: Afatinib; Antineoplastic Agents; Axitinib; Chromatography, Liquid; Drug Stability; Humans; Imidazoles; Indazoles; Lapatinib; Limit of Detection; Linear Models; Micelles; Neoplasms; Quinazolines; Reproducibility of Results | 2018 |
HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Synergism; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinolines; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured | 2019 |
Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Caco-2 Cells; Cell Survival; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Lapatinib; Molecular Targeted Therapy; Oxaliplatin; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Trastuzumab | 2019 |
Efficacy of Afatinib and Lapatinib Against
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Gene Amplification; Humans; Lapatinib; Male; Mice; Mice, Nude; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Quantitative Structure-Mutation-Activity Relationship Tests (QSMART) model for protein kinase inhibitor response prediction.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Humans; Lapatinib; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Neural Networks, Computer; Precision Medicine; Protein Interaction Maps; Protein Kinase Inhibitors; Quantitative Structure-Activity Relationship | 2020 |
Study on the prognosis, immune and drug resistance of m6A-related genes in lung cancer.
Topics: Adenosine; Afatinib; Crizotinib; Dasatinib; Drug Resistance; Erlotinib Hydrochloride; Etoposide; Humans; Lapatinib; Lung Neoplasms; Tumor Microenvironment; Ubiquitin-Protein Ligases | 2022 |
In Vitro and In Silico Studies of Kinase Inhibitor of MAPK3 Protein to Determine Leishmania martiniquensis Treatment.
Topics: Afatinib; Animals; Antineoplastic Agents; Antiprotozoal Agents; Escherichia coli; Female; Lapatinib; Leishmania donovani; Leishmaniasis; Protein Kinase Inhibitors | 2023 |
Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer.
Topics: Afatinib; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Humans; Lapatinib; Mutation; Neoplasms; Protein Kinase Inhibitors; Receptor, ErbB-2; Trastuzumab | 2023 |